These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17997799)

  • 1. Choices and challenges in endocrine treatment for breast cancer.
    Murta EF; Nomelini RS
    Int J Clin Pract; 2007 Dec; 61(12):1962-4. PubMed ID: 17997799
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
    Ellis MJ
    J Clin Oncol; 2005 Aug; 23(22):4842-4. PubMed ID: 15998901
    [No Abstract]   [Full Text] [Related]  

  • 3. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
    Farkas A; Ananth CV
    Obstet Gynecol; 2005 Jan; 105(1):218; author reply 218-9. PubMed ID: 15625172
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
    Parton M; Smith IE
    J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hormonal therapy in breast cancer].
    Espinós J; Reyna C; de la Cruz S; Oiler C; Hernández A; Fernández Hidalgo O; Santisteban M; García Foncillas J
    Rev Med Univ Navarra; 2008; 52(1):40-8. PubMed ID: 18578196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does hormonal therapy decrease tamoxifen associated hot flashes?
    Barton DL; Loprinzi CL
    Breast Cancer Res Treat; 2009 Aug; 116(3):529-30. PubMed ID: 19205876
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiation beats tamoxifen after DCIS treatment.
    Health News; 2003 Sep; 9(9):8. PubMed ID: 14584475
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the impact of tamoxifen on radiation-induced fibrosis in patients receiving breast-conserving therapy.
    Koc M
    J Clin Oncol; 2007 Dec; 25(36):5841; author reply 5844-5. PubMed ID: 18089889
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
    Fabian C
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
    [No Abstract]   [Full Text] [Related]  

  • 13. By the way, doctor. Should I switch from tamoxifen to an aromatase inhibitor?
    Robb-Nicholson C
    Harv Womens Health Watch; 2007 Jun; 14(10):8. PubMed ID: 18018318
    [No Abstract]   [Full Text] [Related]  

  • 14. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ductal carcinoma in situ.
    Venniyoor A
    Aust Fam Physician; 2006 May; 35(5):278-9; author reply 279. PubMed ID: 16708448
    [No Abstract]   [Full Text] [Related]  

  • 17. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly diagnosed angina.
    Geiger AM; Bernstein L
    Cancer; 2006 Jan; 106(2):480-1; author reply 481. PubMed ID: 16311985
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary prevention of breast cancer: whither tamoxifen?
    Rouse DJ
    Obstet Gynecol; 2004 Sep; 104(3):431-2. PubMed ID: 15339750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.